Why the Immuron (ASX:IMC) share price is rocketing up 10% today

The Immuron Limited (ASX: IMC) share price is surging today following a research agreement with Monash University for combating COVID-19.

The Immuron Ltd (ASX: IMC) share price is surging today following a research agreement with Monash University for combating COVID-19. At the time of writing, the Immuron share price is up 10.42% to 26.5 cents.

Immuron is clinical-stage biopharmaceutical company focused on the development and commercialisation of a novel class of specifically targeted polyclonal antibodies. The company researches and develops hyperimmune products for markets in Australia, the United States and Canada.

Product sales comprise Travelan and Protectyn, which is used for the prevention of travellers' diarrhoea.

A happy businessman pointing up, inidicating a rise in share price

Image source: Getty Images

What's pushing the Immuron share price higher?

The Immuron share price has been a positive mover today compared to the broader All Ordinaries Index (ASX: XAO) which is down 0.3% to 6.877 points.

According to today's release, Immuron advised that its hyperimmune bovine colostrum, called 'IMM-124E' has shown antiviral activity against COVID-19 in a laboratory. The hyperimmune bovine colostrum is used currently in the company's key products, Travelan and Protectyn.

To further support the promising results, Immuron has partnered with Monash University to undertake further research. The agreement will see Monash University examine and evaluate the efficacy of IMM-124E against the COVID-19 virus.

This follows the company's previous efforts in engaging with domestic and international researchers to advance its work.

What is hyperimmune bovine colostrum?

Bovine colostrum is a milky fluid that comes from the udder of cows the first few days after giving birth.

This fluid contains proteins called antibodies that can fight bacteria and viruses that cause diseases. Antibody levels in bovine colostrum can be 100 times higher than levels in regular cow's milk.

Researchers have created a special type of bovine colostrum called 'hyperimmune bovine colostrum'. It's produced by cows that have received vaccinations against specific disease-causing organisms and is high is specific kinds of antibodies.

Bovine colostrum is most commonly used to treat diarrhea and other infections.

What did the research team from Monash University say?

Microbiology Department deputy head, Professor Dena Lyras, said the university had been fortunate to obtain access to the SARS-CoV-2 recombinant proteins developed at the Peter Doherty Institute for Infection and Immunity.

Dr Melanie Hutton went on to talk about the research team's plan, saying:

These reagents will be used to initiate the research work and to develop a suitable assay for evaluating the inhibitory efficacy of IMM-124E.

Furthermore, specific immune components will be purified from IMM-124E and will be used to evaluate their ability to inhibit the binding of an antibody positive human serum sample to specific COVID-19 proteins, such as the spike protein which is crucial for cell entry.

Immuron share price summary

Investors are likely to have a mixed response to the Immuron share price. Although its shares have risen more than 85% in the past 12 months, short-term charts show the Immuron share price on a gradual decline.

The company's shares did see a sharp spike in July reaching 95 cents, following a market update to IMM-124E. However, the share price quickly came crashing down as investors pocketed the profit.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

Happy wife holding her hands on her husband's shoulders while both look at a laptop.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man stands in front of a chart with an arrow going down and slaps his forehead in frustration.
ASX Share Market News

ASX 200 mining shares smashed in major market sell-off

The ASX 200 fell 5.39% amid a mining sell-off, with BHP shares tumbling almost 13% last week.

Read more »

A woman weraing a stripy t-shirt winks as she points to the decorative gold crown on her head.
ASX Share Market News

CBA shares back on top of the ASX 200 as BHP dives 13% this week

CBA shares have rallied 9.5% over the past month whilst BHP tumbled 13% this week.

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.
IPOs

Anthropic hits the market. Was it enough to distract investors from a bruised AI sector and Nvidia's scandal?

Was the biggest IPO in US history enough to re-energise the AI trade?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »